

Anything we can do to protect the drug pack without changing the look of it is high on my priority list because additions and changes can require regulatory approval.

Brand Protection
Technologies Manager



CASE STUDY

Global Pharmaceutical Leader Uses Digital Authentication to Stem Counterfeiting and Diversion in High-Risk Market

Customer

A patient-focused, global pharmaceutical brand that builds on a distinguished 235-year history to develop highly innovative medicines. Their operations span over 70 regions worldwide with products marketed in approximately 100 countries. This values-based leader has a longstanding relationship with Systech.

Challenge

As a participant in the Access to Medicine (AtM) program the company provides specialized drugs for GI, oncology and vaccines to patients in underserved regions that also are at highest risk for counterfeiting and product diversion.

Committed to patient health, the company launched a global product protection project to strengthen supply chain security in highcounterfeiting areas including Kenya, the Philippines and Ukraine. According to their Brand Protection Technologies Manager, "Serialization by itself will not end counterfeiting. It will help address the problem but won't end it altogether."

The company faces three major challenges in these markets:

- High concentrations of counterfeit goods and minimal or no anti-counterfeit regulations.
- Parallel trade, which is legal in the European Union (EU), increases the appetite for product diversion. More product diversion channels provide more and easier insertion points for counterfeit goods.
- Loss of visibility once their products leave the manufacturing facility, making it difficult to tighten protections at the tail end of the supply chain.

I like that Systech's solution doesn't require any type of proprietary reader that you have to keep track of and provide to partners.



Systech is revolutionizing brand protection. For over 30 years, global brands have relied on us to combat counterfeiters, prevent product diversion and meet regulatory compliance. Innovation is deeply engrained in our DNA—from our start-up roots in advanced machine vision to pioneering pharmaceutical serialization and transforming traceability and non-additive authentication. Our software solutions ensure products are authentic, safe and connected across the supply chain—from manufacturing to the consumer's hands.

Contact Us

US Headquarters: +1 800 847 7123 UK Office: +44 1482 225118 EU Office: +32 2 467 03 30 India Office: +91 22 4541 1400 <u>China Office: +86 21 51798418</u>

SystechOne.com Marketing@SystechOne.com



© 2019 Systech. All rights reserved. 03/19

Solution

For its initial product protection project, the company established digital authentication for oncology medicines manufactured in the EU before shipment to Kenya. The solution incorporated technology from the Systech Brand Protection Suite™ to establish anti-counterfeit and anti-diversion protections that worked with measures already in place.

The pharmaceutical leader takes a multi-layered approach to anticounterfeiting—understanding that serialization is critical but not sufficient protection against counterfeiting. The new solution creates a unique digital signature, or "e-Fingerprint®," based on micro-variances in the existing barcode on each package. The e-Fingerprint is stored on a secure cloud, then used to authenticate products at the individual item level through a smartphone app.

To reduce product diversion, the solution incorporated Systech's trackand-trace system to implement the supply chain visibility the company needed. The enterprise-wide platform integrates internal and external serialized item information systems to provide real-time data on any unique package from the factory to the administering physician.

Results

The digital authentication solution established effective protection for some of the company's highest-value products in one of its highest-risk markets. The solution has been an excellent fit for the African market, where cellphone usage rates are high even in less technologically developed areas.

Implementation was extremely fast and cost-effective compared to other anti-counterfeiting measures that could include packaging changes or major production line overhauls. From initial hardware installation on the first packaging line to product testing, implementation took four days, with validation adding another two.

The success and relatively low cost of the pilot program demonstrated the potential for wide-scale implementation because the solution is:

- Non-additive Leveraged existing packaging for covert protection, so no need for art changes or line overhauls
- Secure Cannot be reverse-engineered, removed or duplicated
- **Simple** Mobile app for authentication works with standard smartphones, reducing complexity and eliminating expense of specialized readers
- **Globally accessible** Traceability and authentication from anywhere in the world for products at any point in the supply chain down to administering physicians

"For the first line we installed this on, the plant manager was so pleased with the technology that he came up with the money for the initial install of the hardware,"

- Brand Protection Technologies Manager

Next Steps

Now that the solution has been proven in one of the company's highestrisk markets, the pharmaceutical leader is looking to deploy the anticounterfeiting and diversion detection solution into other product lines in different regions around the globe.